MicroVigeneTM 2.0 extends VigeneTech’s flagship microarray image
analysis software to support Reserve Phase Protein Microarray analysis.
The new release is a result of close collaboration between VigeneTech
and the inventors of the Reverse Phase Protein Microarray methodology
-the teams of Dr. Lance Liotta, Chief, Laboratory of Pathology, NIH/NCI
and Dr. Emanuel Petricoin, Co-Director, NCI-FDA Clinical Proteomics
Program. Scientists of both
research teams are now routinely using the software.
MicroVigeneTM 2.0 significantly
speeds up the data analysis process of the Reserve Phase Protein
Microarray analysis, offers powerful tools to support various image
layouts and dilution curve designs, and brings this exciting technology
to a new level of implementation whereby reproducibility, precision and
accuracy can be analyzed very quickly. The deployment of MicroVigeneTM
2.0 is a significant step toward high quality and reproducible standard
procedure of Reverse Phase Protein Microarray analysis for the NCI-FDA
clinical proteomics program and eventual clinical implementation.
2.0 provides an all-in-one, integrated and automatic solution for the
Reverse Phase Protein Microarray image analysis process.
This will turn the time consuming tasks to a single mouse click
-from several hours or a day to a few minutes. The novel data analysis
process for all dilution curves and system standards allows data
comparison among different studies and clinical trials.
The software's modular design and open architecture allows the
system to be incorporated into any customized data analysis process.
feedback from scientists at NIH and FDA played a big role in the
development of this new MicroVigeneTM
product release. The success of this release in such a short time, and
met all the specifications requested by NCI-FDA scientists also
demonstrates the remarkable strength and the flexibility of MicroVigeneTM
development team. This new
release marked the extension of our products and services to protein
microarray and customized image and data analysis software
development,” said Dr. Minzi Ruan, CEO of VigeneTech.
The goal of the FDA-NCI Clinical Proteomics Program is to invent and apply proteomics
technology to patient care. New
proteomics research technology is now being used for clinical studies
ranging from cancer to cardiovascular disease and organ transplant.
Researchers within the program are searching for proteins in the
blood, urine, and diseased tissue that can be used as early biomarkers
of disease, predict response to therapy, or the likelihood of relapse
after treatment, or serve as new targets for therapy itself.
Inc.: VigeneTech provides novel scientific software, customized
solutions and online services in the areas of image analysis,
automation, and instrumentation. VigeneTech’s MicroVigeneTM
for microarray image analysis delivers 100% reproducible, operator
independent results; it is robust to handle various shifted and noisy
images; and supports unattended batch process.
For more information about VigeneTech, please visit http://www.vigenetech.com.